BWXT targets $4.70-$4.80 EPS and raises 2026 free cash flow outlook to $345M-$360M amid medical sale
BWXT announced that it aims for an EPS of $4.70‑$4.80 in 2026 through the sale of its medical segment and has revised its free cash flow guidance to $345M‑$360M.
As of August 24, 2026, the closing price of $149.52 is positioned below the support level of $157.10, suggesting a potential for a rebound, but given the wide distance from the resistance level, the upside potential is deemed limited.
If the price rises to $195.32 (resistance level), take profits based on the REPORTING output, and if the price falls to $157.10 (support level), cut losses.
RSI(14) 42.3, moving averages are misaligned, trading volume is 1.10 times the 20-day average – neutral momentum with slight upward pressure.
The forecast anticipated a 1.5% increase, but the actual return was -12.5%, falling below the stop-loss level of $157.10, resulting in a stop-loss trigger. While the EPS and cash flow projections were accurate, the sharp decline in price was overlooked.
In the next trade, we will enter after confirming a clear rebound signal near the support level (e.g., RSI oversold, surge in trading volume) and set the stop-loss closer to limit risk.